Poor
Not Aligned
Patient Risk:
Low
Summary
Only one claim is directly supported by the provided FDA label text (Description: synthetic liothyronine/LT3). The majority of claims are not supported by the provided label sections; several are promotional/market-knowledge statements that are absent from the label. One claim about sensitivity to dose changes is only partially supported (monitoring adequacy), not explicitly stated in the excerpt.
Category Scores
Accurate Statements
Liothyronine is the synthetic form of the thyroid hormone T3 (triiodothyronine).
11 DESCRIPTION: "CYTOMEL tablets contain the active ingredient, liothyronine (L-triiodothyronine or LT3), a synthetic form of a thyroid hormone liothyronine in sodium salt form."
Unsupported Statements
In the US, Cytomel is one of the best-known brand names for liothyronine.
No support in the provided label sections.
Cytomel is the primary well-known brand associated with liothyronine therapy.
No support in the provided label sections.
The active ingredient in brand-name liothyronine and generic liothyronine is the same (liothyronine).
Not stated in the provided label sections; only general absence from provided text.
Generics typically cost less than the branded version of liothyronine.
Cost comparisons are not included in the provided label sections.
Patients and clinicians usually focus on dose (mcg) and consistent prescribing for liothyronine.
Behavioral/practice claims are not stated in the provided label sections.
Contradictions
Low
AI Statement
None identified as directly conflicting with the provided FDA label excerpts.
Label Reference
Important Omissions
No evaluation of FDA label elements such as indications, boxed warnings, contraindications, dosage/administration, drug interactions, adverse reactions, or detailed monitoring instructions was possible because no label text for those sections was provided for comparison.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only directly supported claim is descriptive (active ingredient is synthetic liothyronine/LT3). Unsupported/promotional claims and the partially supported monitoring implication do not, based on provided evidence, constitute direct safety/usage instructions. However, lack of label-wide review limits certainty.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most extracted claims are not supported by the provided FDA label text.
Suggested Improvement
Limit assertions to statements explicitly supported by the supplied label excerpts (e.g., Description and Monitoring language). Remove or qualify market/typical-practice/cost claims that are absent from the label, and replace general statements like 'sensitive to dose changes' with label-supported monitoring/assessment wording.